Welcome to our dedicated page for Repligen news (Ticker: RGEN), a resource for investors and traders seeking the latest updates and insights on Repligen stock.
Repligen Corporation (NASDAQ: RGEN) is a global life sciences company headquartered in Waltham, Massachusetts, focused on bioprocessing technologies and systems that support the manufacturing of biological drugs. This news page aggregates company announcements, earnings updates, product launches and strategic developments directly related to Repligen’s operations in bioprocessing.
According to its public communications, Repligen serves primarily biopharmaceutical drug developers and contract development and manufacturing organizations (CDMOs), with core focus areas in Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. News items often highlight how these focus areas evolve through new products, partnerships and technology integrations.
Investors and industry followers can use this page to review earnings press releases and related Form 8-K announcements, which cover quarterly financial results, guidance updates and commentary on demand trends across Repligen’s franchises and geographies. The company’s releases also discuss the use of non-GAAP financial measures and provide reconciliations to GAAP results.
Repligen’s news flow additionally includes product and technology updates, such as the launch of new chromatography resins in its proteins portfolio and introductions of equipment in areas like mixing and process analytics. Strategic partnerships, including its collaboration with Novasign to integrate machine learning and modeling workflows into Repligen filtration systems, are another recurring theme.
Governance and leadership developments, such as Board chair transitions and senior finance appointments disclosed via press releases and Form 8-K filings, also appear in the news stream. By checking this page regularly, readers can follow how Repligen describes its progress in bioprocessing technology leadership, digitalization initiatives, and its engagement with the biopharmaceutical and CDMO sectors.
Repligen (NASDAQ: RGEN) announced that Dr. Martin D. Madaus was elected Chair of the Board effective March 13, 2026, as Executive Chair Tony Hunt retires from the Board on that date and will remain as an advisor through March 2027. Dr. Madaus has served as a Repligen director since February 2023 and brings 36 years of industry experience, including five years as Chairman, President and CEO of Millipore and involvement in its 2010 acquisition by Merck KGaA. Dr. Madaus also serves on the boards of Azenta and Hologic and holds a D.V.M. and Ph.D. from universities in Germany.
Repligen (NASDAQ:RGEN) will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco, January 12–15, 2026.
Olivier Loeillot, President and CEO, will deliver an overview of the company on Tuesday, January 13 at 2:15 p.m. PT. A live webcast will be available on Repligen’s investor relations website and will be replayable for a limited period after the event.
Repligen (NASDAQ:RGEN) announced three new high-performance chromatography resins on Dec. 16, 2025: AVIPure HiPer AAV9, AVIPure HiPer AAV8 affinity resins and HiPer QA anion exchange resin. Built on Tantti DuloCore base bead technology, the convective HiPer resins target next‑generation modalities such as viral vectors and gene therapy.
The company says the resins are engineered to help gene therapy developers accelerate product development, improve molecule stability, and enhance process economics, and that the launch strengthens Repligen's proteins portfolio ahead of broader chromatography resin rollouts planned for 2026.
Repligen (NASDAQ:RGEN) will participate in the 8th Annual Evercore Healthcare Conference taking place Dec 2–4, 2025 in Coral Gables, Florida.
Jason Garland, Chief Financial Officer, will join an analyst-led discussion on Dec 3, 2025 at 1:20 p.m. ET. A live webcast will be available on Repligen’s Investor Relations website at www.repligen.com, with a limited-time replay following the event.
Repligen (NASDAQ:RGEN) will attend five investor conferences in November 2025 with executive participation and webcasts available. Key events: UBS Global Healthcare (Nov 10–12, Palm Beach Gardens; CFO Jason Garland on Nov 10 at 11:00 a.m. ET), Stifel Healthcare (Nov 11–13, New York; CEO Olivier Loeillot on Nov 11 at 10:00 a.m. ET), Wolfe Research Healthcare (Nov 17–19, New York; CFO Jason Garland on Nov 18 at 12:40 p.m. ET), Jefferies Global Healthcare (Nov 18–20, London; CEO Olivier Loeillot on Nov 18 at 8:30 a.m. ET/1:30 p.m. GMT), and Stephens Annual Investment (Nov 18–20, Nashville; CFO one-on-ones on Nov 19).
A live webcast of presentations will be available on Repligen’s Investor Relations website and replayed for a limited time.
Repligen (NASDAQ:RGEN) reported Q3 2025 revenue of $189M, up 22% reported and 18% organic year‑over‑year, and raised full‑year revenue guidance to $729M–$737M. The company said all franchises and geographies posted double‑digit growth, consumables and capital equipment grew >20%, and Process Analytics equipment placements hit a record quarter after the SoloVPE PLUS launch.
Q3 GAAP net income was $15M and adjusted net income was $26M; GAAP EPS was $0.26 and adjusted EPS was $0.46. Cash and cash equivalents were $749M at Sept 30, 2025. FY2025 adjusted guidance includes organic, non‑COVID growth of 14%–15.5%, adjusted operating income of $98M–$100M, and adjusted EPS of $1.65–$1.68.
Repligen (NASDAQ:RGEN) will report its third quarter 2025 financial results on Tuesday, October 28, 2025. A press release will be issued before the market opens, followed by a conference call at 8:30 a.m. ET to discuss business updates and results for the three- and nine-month periods ended September 30, 2025.
The live call is accessible toll-free at (800) 715-9871 (U.S.) or (646) 307-1963 (international) with no passcode required. A webcast will be available and archived via the company Investor Relations website, and a replay will be posted after the event.
Repligen Corporation (NASDAQ:RGEN), a bioprocessing technology leader in life sciences, has announced its participation in three major healthcare conferences in September 2025:
- Wells Fargo Healthcare Conference (Sept 3-5, Boston) - CEO Olivier Loeillot to join analyst discussion on Sept 4 at 8:00 a.m. ET
- Deutsche Bank Healthcare Summit (Sept 10-11, NYC) - CFO Jason Garland to hold 1x1 meetings on Sept 10
- Bank of America Global Healthcare Conference (Sept 23-25, London) - CEO Olivier Loeillot to participate in analyst discussion on Sept 25 at 6:35 a.m. ET
Live webcasts will be available on Repligen's Investor Relations website with limited-time replay access.
Repligen (NASDAQ:RGEN) has announced a strategic partnership with Novasign to enhance its bioprocessing digitalization capabilities. The collaboration involves integrating Novasign's machine learning and modeling workflow into Repligen's tangential flow filtration (TFF) systems.
As part of the agreement, Repligen will make an investment in Novasign to support its expansion. The partnership aims to leverage digital twins technology and AI-powered solutions to streamline process development, enable real-time predictive control, and reduce development timelines and costs in bioprocessing operations.
The integration will strengthen Repligen's Process Analytical Technology (PAT)-enabled systems and create opportunities for advanced AI modeling within Repligen platforms.
Repligen (NASDAQ:RGEN) reported strong Q2 2025 financial results with revenue reaching $182 million, marking a 15% year-over-year increase and 17% organic non-COVID growth. The company demonstrated robust performance with orders growing over 20% year-over-year, marking the eighth consecutive quarter of orders exceeding non-COVID revenue.
Key financial metrics include GAAP net income of $15 million ($0.26 per share) and adjusted net income of $21 million ($0.37 per share). The company maintains a strong balance sheet with $709 million in cash and equivalents.
Based on strong execution and visibility, Repligen increased its full-year 2025 revenue guidance to $715-$735 million, representing 12.5-15.5% year-over-year non-COVID organic growth. The company launched ProConnex® MixOne and published its 2024 Sustainability report.
FAQ
What is the current stock price of Repligen (RGEN)?
What is the market cap of Repligen (RGEN)?
